TY - JOUR
T1 - Safety and serological response to a matrix gene-deleted rabies virus-based vaccine vector in dogs
AU - McGettigan, James P.
AU - David, Frederic
AU - Figueiredo, Monica Dias
AU - Minke, Jules
AU - Mebatsion, Teshome
AU - Schnell, Matthias J.
PY - 2014/3/26
Y1 - 2014/3/26
N2 - Dogs account for the majority of human exposures and deaths due to rabies virus (RABV) worldwide. In this report, we show that a replication-deficient RABV-based vaccine in which the matrix gene is deleted (RABV-δM) is safe and induces rapid and potent VNA titers after a single inoculation in dogs. Average VNA titers peaked at 3.02 or 5.11 international units (IU/ml) by 14 days post-immunization with a single dose of 106 or 107 focus forming units (ffu), respectively, of RABV-δM. By day 70 post immunization, all dogs immunized with either dose of vaccine showed VNA titers >0.5IU/ml, the level indicative of a satisfactory immunization. Importantly, no systemic or local reactions were noted in any dog immunized with RABV-δM. The elimination of dog rabies through mass vaccination is hindered by limited resources, requirement for repeat vaccinations often for the life of a dog, and in some parts of the world, inferior vaccine quality. Our preliminary safety and immunogenicity data in dogs suggest that RABV-δM might complement currently used inactivated RABV-based vaccines in vaccination campaigns by helping to obtain 100% response in vaccinated dogs, thereby increasing overall vaccination coverage.
AB - Dogs account for the majority of human exposures and deaths due to rabies virus (RABV) worldwide. In this report, we show that a replication-deficient RABV-based vaccine in which the matrix gene is deleted (RABV-δM) is safe and induces rapid and potent VNA titers after a single inoculation in dogs. Average VNA titers peaked at 3.02 or 5.11 international units (IU/ml) by 14 days post-immunization with a single dose of 106 or 107 focus forming units (ffu), respectively, of RABV-δM. By day 70 post immunization, all dogs immunized with either dose of vaccine showed VNA titers >0.5IU/ml, the level indicative of a satisfactory immunization. Importantly, no systemic or local reactions were noted in any dog immunized with RABV-δM. The elimination of dog rabies through mass vaccination is hindered by limited resources, requirement for repeat vaccinations often for the life of a dog, and in some parts of the world, inferior vaccine quality. Our preliminary safety and immunogenicity data in dogs suggest that RABV-δM might complement currently used inactivated RABV-based vaccines in vaccination campaigns by helping to obtain 100% response in vaccinated dogs, thereby increasing overall vaccination coverage.
KW - Canine
KW - Rabies
KW - Replication-deficient RABV
KW - Vaccine
UR - http://www.scopus.com/inward/record.url?scp=84895883997&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84895883997&partnerID=8YFLogxK
U2 - 10.1016/j.vaccine.2014.01.043
DO - 10.1016/j.vaccine.2014.01.043
M3 - Article
C2 - 24508037
AN - SCOPUS:84895883997
SN - 0264-410X
VL - 32
SP - 1716
EP - 1719
JO - Vaccine
JF - Vaccine
IS - 15
ER -